T1	Measurement 30 54	Breast - Karnofsky score
T2	Value 55 59	> 50
R1	Has_value Arg1:T1 Arg2:T2	
T3	Measurement 97 147	Gynecologic Oncology Group (GOG) performance score
T4	Value 148 150	â‰¤2
R2	Has_value Arg1:T3 Arg2:T4	
T5	Person 155 161	female
T6	Condition 169 191	childbearing potential
T7	Scope 155 191	female and of childbearing potential
A1	Optional T7
T8	Observation 197 207	willing to
T9	Procedure 221 234	contraception
T10	Drug 236 244	hormonal
T11	Procedure 246 260	barrier method
T12	Procedure 262 272	abstinence
*	OR T10 T11 T12
T13	Scope 236 272	hormonal, barrier method, abstinence
R3	Subsumes Arg1:T9 Arg2:T13	
R4	AND Arg1:T8 Arg2:T9	
R5	Has_context Arg1:T7 Arg2:T8	
T14	Temporal 299 338	for the duration of study participation
T15	Temporal 274 294	prior to study entry
R6	Has_temporal Arg1:T9 Arg2:T15	
T16	Condition 341 362	Normal organ function
T17	Temporal 363 392	within 14 days of study entry
R7	Has_temporal Arg1:T16 Arg2:T17	
T18	Condition 443 467	Metastatic breast cancer
T19	Condition 474 499	Metastatic ovarian cancer
T20	Condition 506 535	Metastatic endometrial cancer
T21	Condition 542 568	Metastatic cervical cancer
T22	Condition 586 604	metastatic disease
T23	Qualifier 575 585	Measurable
R8	Has_qualifier Arg1:T22 Arg2:T23	
T24	Value 606 610	>1cm
*	OR T23 T24
T25	Value 615 627	at least one
T26	Qualifier 628 653	site other than bone-only
R9	Has_qualifier Arg1:T25 Arg2:T26	
R10	AND Arg1:T25 Arg2:T22	
T27	Observation 673 691	failure to respond
T28	Observation 655 669	Progression on
*	OR T27 T28
T30	Temporal 708 716	previous
T31	Procedure 717 737	chemotherapy regimen
T32	Condition 742 760	metastatic disease
R11	AND Arg1:T31 Arg2:T32	
R13	Has_temporal Arg1:T31 Arg2:T30	
T33	Scope 655 691	Progression on or failure to respond
R12	AND Arg1:T33 Arg2:T31	
T29	Observation 762 776	Progression on
T34	Temporal 777 782	prior
T35	Procedure 783 812	therapy with a hormonal agent
T36	Condition 816 833;859 867	estrogen receptor positive
T37	Condition 837 867	progesterone receptor positive
*	OR T36 T37
T38	Scope 816 867	estrogen receptor or progesterone receptor positive
R16	AND Arg1:T38 Arg2:T35	
T39	Condition 896 913	HER2-neu positive
T40	Procedure 783 795;881 892	therapy with trastuzumab
R17	AND Arg1:T39 Arg2:T40	
T41	Scope 777 913	prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive
*	OR T39 T38
R14	Has_temporal Arg1:T35 Arg2:T34	
R15	Has_temporal Arg1:T40 Arg2:T34	
A4	Optional T41
R18	Has_context Arg1:T41 Arg2:T29	
T42	Observation 930 948	progressed through
T43	Procedure 949 956;972 979	hormone therapy
T44	Procedure 960 979	trastuzumab therapy
*	OR T43 T44
T45	Scope 930 979	progressed through hormone or trastuzumab therapy
R19	Has_context Arg1:T45 Arg2:T42	
A2	Optional T45
R20	Has_context Arg1:T43 Arg2:T42	
R21	Has_context Arg1:T44 Arg2:T42	
T46	Procedure 1009 1029	chemotherapy regimen
R22	AND Arg1:T45 Arg2:T46	
T47	Measurement 1076 1129	Response Evaluation Criteria in Solid Tumors (RECIST)
T48	Condition 1043 1061	metastatic disease
R23	AND Arg1:T48 Arg2:T47	
T49	Condition 1195 1220	epithelial ovarian cancer
T50	Procedure 1170 1184	histologically
T51	Qualifier 1131 1144	Primary tumor
R24	Has_qualifier Arg1:T50 Arg2:T51	
T52	Condition 1222 1243	fallopian tube cancer
T53	Condition 1248 1273	primary peritoneal cancer
T54	Qualifier 1279 1289	borderline
T55	Condition 1317 1337	epithelial carcinoma
*	OR T52 T53 T49
T57	Scope 1275 1337	not borderline or low malignant potential epithelial carcinoma
T56	Scope 1195 1273	epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
R26	Has_scope Arg1:T50 Arg2:T56	
T58	Multiplier 1367 1379	at least two
T59	Temporal 1380 1388	previous
T60	Procedure 1389 1410	chemotherapy regimens
R27	Has_temporal Arg1:T60 Arg2:T59	
R28	AND Arg1:T58 Arg2:T60	
T61	Observation 1360 1366	failed
R29	Has_context Arg1:T60 Arg2:T61	
T62	Drug 1412 1422	Paclitaxel
T63	Drug 1478 1487	cisplatin
T64	Drug 1491 1502	carboplatin
T65	Condition 1567 1585	metastatic disease
T66	Qualifier 1556 1566	Measurable
R30	Has_qualifier Arg1:T65 Arg2:T66	
T67	Measurement 1587 1601	Histologically
T68	Value 1602 1608	proven
R31	Has_value Arg1:T67 Arg2:T68	
T71	Scope 1609 1651	recurrent or persistent endometrial cancer
R32	AND Arg1:T71 Arg2:T67	
T72	Qualifier 1664 1694	amenable to curative treatment
T73	Negation 1660 1663	not
R33	Has_qualifier Arg1:T71 Arg2:T72	
R34	Has_negation Arg1:T72 Arg2:T73	
T74	Procedure 1700 1707	surgery
T75	Procedure 1715 1732	radiation therapy
*	OR T74 T75
T76	Scope 1700 1732	surgery and/or radiation therapy
R35	Has_scope Arg1:T72 Arg2:T76	
T77	Value 1748 1749	2
T78	Temporal 1750 1758	previous
T79	Procedure 1759 1777	treatment regimens
R36	AND Arg1:T77 Arg2:T79	
R37	Has_temporal Arg1:T79 Arg2:T78	
T80	Observation 1741 1747	failed
R38	Has_context Arg1:T79 Arg2:T80	
R39	Has_scope Arg1:T79 Arg2:T71	
T81	Condition 1790 1808	metastatic disease
T82	Qualifier 1779 1789	Measurable
R40	Has_qualifier Arg1:T81 Arg2:T82	
T83	Measurement 1810 1824	Histologically
T84	Value 1825 1831	proven
R41	Has_value Arg1:T83 Arg2:T84	
T85	Condition 1856 1879	squamous cell carcinoma
T86	Qualifier 1845 1855	persistent
T87	Qualifier 1832 1841	recurrent
*	OR T87 T86
T88	Scope 1832 1855	recurrent or persistent
T89	Condition 1881 1904	adenosquamous carcinoma
T90	Condition 1909 1937	adenocarcinoma of the cervix
T91	Qualifier 1950 1980	amenable to curative treatment
T92	Negation 1946 1949	not
R44	Has_negation Arg1:T91 Arg2:T92	
T93	Procedure 1986 1993	surgery
T94	Procedure 2001 2018	radiation therapy
T95	Value 2034 2035	2
T96	Procedure 2045 2063	treatment regimens
T97	Temporal 2036 2044	previous
R45	AND Arg1:T95 Arg2:T96	
R46	Has_temporal Arg1:T96 Arg2:T97	
*	OR T94 T93
T69	Condition 1633 1651	endometrial cancer
T70	Qualifier 1622 1632	persistent
T98	Qualifier 1609 1618	recurrent
*	OR T98 T70
T99	Scope 1609 1632	recurrent or persistent
R47	Has_scope Arg1:T69 Arg2:T99	
T100	Scope 1856 1937	squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
R42	Has_scope Arg1:T100 Arg2:T88	
R43	AND Arg1:T100 Arg2:T83	
R48	Has_qualifier Arg1:T100 Arg2:T91	
R49	AND Arg1:T91 Arg2:T93	
R50	Has_scope Arg1:T96 Arg2:T100	
T101	Negation 1275 1278	not
T102	Qualifier 1293 1316	low malignant potential
T103	Scope 1279 1316	borderline or low malignant potential
*	OR T102 T54
R25	Has_scope Arg1:T55 Arg2:T103	
R51	Has_negation Arg1:T55 Arg2:T101	
R52	Has_scope Arg1:T56 Arg2:T57	
*	OR T63 T64
T104	Scope 1412 1553	Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens
R53	Has_scope Arg1:T60 Arg2:T104	
R54	Has_temporal Arg1:T9 Arg2:T14	
T105	Reference_point 283 294	study entry
R55	Has_index Arg1:T15 Arg2:T105	
T106	Reference_point 319 338	study participation
R56	Has_index Arg1:T14 Arg2:T106	
T107	Reference_point 381 392	study entry
R57	Has_index Arg1:T17 Arg2:T107	
T108	Qualifier 62 69	Ovarian
T109	Qualifier 71 82	endometrial
T110	Qualifier 86 94	cervical
*	OR T109 T110 T108
T111	Scope 62 94	Ovarian, endometrial or cervical
R58	Has_scope Arg1:T3 Arg2:T111	
T112	Measurement 9 27	performance status
T113	Value 0 8	Adequate
R59	Has_value Arg1:T112 Arg2:T113	
T114	Non-representable 0 27	Adequate performance status
